LETTER FROM THE PRESIDENT
This was a key year for us as we further developed the Penta strategic plan, the strategic plans for each scientific content area and platform and held our bi- annual Penta Investigator’s Meeting.
We haven’t just made strides forward in terms of our strategic direction; we have also made great progress in our strategic clinical trials. We have exceeded our recruitment target in the SMILE study by recruiting 318 patients, closed recruitment in the NeoVanc project with 240 patients enrolled for the study as well as achieved our recruitment target of 150 patients for the EARTH study.
We have also completed the PED-MERMAIDS study, which has been pivotal in contributing to the standardized data on clinical characteristics, management and outcome of children hospitalized for acute respiratory infections and Antibiotic Resistant Infections and sepsis in Europe. These data will form an incredibly informative pre COVID-19 baseline comparison.
You can read the letter and the report in full here.